IRON DEPOSITS BY NUCLEAR RESONANCE SCATTERING

在地中海贫血中，铁的营养吸收增加， 输血会导致铁超负荷 这些铁矿床可能发生在 许多器官和组织在身体上的有害影响， 病人的健康。 在改善临床管理的研究中， 重型地中海贫血，通过螯合疗法降低铁负荷的方法 正在接受调查。 这些研究由于缺乏 体内铁储存量的灵敏定量测量。 以下 该提案提供了一种独特的定量，非侵入性的铁测量方法 在上述螯合治疗计划中应用的存款， 定量评估其有效性。 铁的体内储存的定量依赖于一种新开发的 核共振散射技术。 在这项技术中， 的56 Fe（92%同位素丰度）被提升到第一激发态， 伽马射线 受激核通过发射 847千电子伏的伽马射线 这种伽马射线是通过特殊的探测器 仪器仪表 在最初的三年里，病人辐照设施是 灵敏度不断提高。 原型设施， 由单独的砖块和钨条建成，被不锈钢取代。 专门设计用于容纳可更换的钢制矩形容器 准直器和一次性熔炉。 肝脏的铁含量， 28例地中海贫血患者和4例血色素沉着症患者心脏 迄今为止，已经测量了过载。 在下一阶段，这个设施将被用来测量铁的变化 地中海贫血患者和含铁血黄素沉着症患者中的沉积物， 血色病目前正在接受螯合治疗。 具体 需要回答的问题是，目前的螯合疗法 有效地稳定或减少铁储存在心脏和肝脏 输血依赖性铁超载患者。

In Thalassemia, both increased iron alimentary absorption and repeated transfusions can cause iron overload. These iron deposits may occur in many organs and tissues in the body with deleterious effects on the patients health. In the research leading to improved clinical management of Thalassemia major, methods of reducing iron burdens by chelation therapy are being investigated. These studies have been hampered by the lack of sensitive quantitative measure of body stores of iron. The following proposal offers a unique quantitative, non-invasive measure of iron deposits to be applied in the above chelation therapy programs in order to evaluate quantitatively their effectiveness. The quantification of body stores of iron rests on a newly developed technique of nuclear resonance scattering. In this technique, the nucleus of 56Fe (92% isotopic abundance) is raised to its first excited state by gamma radiation. The excited nucleus decays to ground state by emission of the 847 KeV gamma-ray. This gamma ray is measured by special detection instrumentation. During the initial three years the patient irradiation facility was continually improved in sensitivity. The prototype facility which was built from separate bricks and tungsten bars, was replaced by a stainless steel rectangular container designed specially to accommodate exchangeable collimators and disposable furnaces. The iron content of the liver and heart of 28 Thalassemic patients and 4 patients with hemochromatosis iron overloads have been measured, to date. In the next phase, this facility will be used to measure changes in iron deposits in Thalassemic patients and patients with hemosiderosis and hemochromatosis currently undergoing chelation therapy. The specific question to be answered is whether the current chelation therapy effectively stabilizes or reduces iron stores in the heart and liver of transfusion dependent iron overloaded patients.